FDA approves first therapy for symptomatic dermographism - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves first therapy for symptomatic dermographism

The oral BTK inhibitor produced a complete hive response in 29.3% of treated patients at week 12.

  • By

  • Teraya Smith

  • October 7, 2026

  • 2 min

Share

Original Source(s)

FDA approves first therapy for symptomatic dermographism

  • by Teraya Smith

  • October 7, 2026

Related Content

Informatics-Based Psychotherapeutic and Psychiatric Interventions in Dermatology: Scoping Review of Impacts on Skin Disease Severity and Mental Health Outcomes

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

10 states that support physician work-life balance

These 10 states have paid family or medical leave programs and health, wellness, peer support, or monitoring resources available to physicians or other health professionals.